[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"immune-system-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:immune-system-disorder":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,43,69,109,139,168,196],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100355499","phase-2-thinking-zinc-a-study-of-zinc-supplements-on-the-navajo-nation-100355499",false,"NCT03908736","Thinking Zinc: a Study of Zinc Supplements on the Navajo Nation","Thinking Zinc: A Study of Zinc Supplementation to Ameliorate Adverse Effects of Mine Waste Exposure on the Navajo Nation","Inclusion Criteria:\n\n* Men or women between the ages of 21 and 64 years of age\n* Lives in or near the participating communities of Blue Gap-Tachee Arizona or Red Water Pond Road Community New Mexico\n* Willing to provide blood and urine samples\n* Willing to attend study visits on scheduled dates\n* Willing to take a daily zinc supplement\n\nExclusion Criteria:\n\n* Women who are pregnant or nursing or women who plan to become pregnant during the course of the study.\n* Individuals who have self-reported diabetes, report that they are undergoing treatment for diabetes, or are currently taking medication for diabetes.\n* Known or suspected allergy to zinc.\n* Individuals previously diagnosed with syndromes of copper homeostasis (Menkes disease or Wilsons disease).\n* Individuals consuming zinc supplements or multivitamins and are unwilling to stop for the duration of the study.",true,"ALL","21 Years","64 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","This is a study to assess the effect of dietary zinc supplementation to mitigate biomarkers of metal toxicity in exposed tribal populations.",[28,29],"DNA Damage","Immune System Disorder","RECRUITING","2026-06-02",{"date":33,"type":34},"2026-06-04","ACTUAL",{"date":36,"type":34},"2019-05-19",{"date":38,"type":22},"2027-12",{"name":40,"class":41},"University of New Mexico","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":16,"sex":17,"minAge":50,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":42},"100301727","collection-of-immunology-specimens-from-patients-with-cancer-or-blood-disorders-and-healthy-volunteers-100301727","NCT03207854","Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers","Protocol for Immunology Specimen Collection From Cancer Patients, Patients With Hematologic Diagnoses, and Healthy Normal Controls","Inclusion Criteria:\n\n* All patients known to have cancer, an immune-mediated hematologic diagnosis, or a healthy normal volunteer\n* Definition of immune-mediated hematologic diagnosis: diagnoses for which immune dysfunction and\u002For immune system directed therapy (eg. aplastic anemia, autoimmune hemolytic anemia, immune thrombocytopenic purpura \\[ITP\\], etc.) are involved\n* Definition of healthy normal volunteer: persons lacking diagnoses of any type of cancer, diabetes, cardiovascular diseases, non-hematologic autoimmune disease (eg. systemic lupus erythematosus \\[SLE\\], rheumatoid arthritis \\[RA\\], Crohn's disease) and not taking any immunosuppressive medications\n* Patients must have been seen in the Norris Hospital and outpatient clinics, or the Los Angeles County (LAC)-University of Southern California (USC) Medical Center or outpatient clinics; healthy volunteers can be recruited without any physician visit appointments since their labs are strictly for clinical research and not for personal health issues unrelated to the project\n\nExclusion Criteria:\n\n* Unable to give informed consent to specimen collection\n* Known human immunodeficiency virus (HIV) positive status\n* Persons taking any type of immunosuppressive medication are excluded from participating as healthy normal volunteers\n* Any patient for whom specimen collection is judged to be unsafe (for example, for patients unable to establish venous access)","19 Years",{"count":52,"type":22},625,"OBSERVATIONAL","This research trial collects and stores blood, tissue, and bone marrow specimens from patients with cancer or blood disorders, and healthy volunteers to study the immune system in a variety of different types of experiments, as well as associated clinical data as appropriate, focused on understanding mechanisms of immunotherapy.",[56,57,58,29,59],"Healthy Subject","Hematologic and Lymphocytic Disorder","Hematopoietic and Lymphoid Cell Neoplasm","Malignant Neoplasm","2026-03-27",{"date":62,"type":34},"2026-04-02",{"date":64,"type":34},"2017-04-12",{"date":66,"type":22},"2027-12-31",{"name":68,"class":41},"University of Southern California",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":16,"sex":17,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":81,"studyType":53,"phases":4,"briefSummary":82,"conditions":83,"keywords":87,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":42},"100449993","montreal-immune-related-adverse-events-mirae-study-100449993","NCT05139706","Montreal Immune-Related Adverse Events (MIRAE) Study","Montreal Database and Biorepository of Cancer Patients Treated With Immune Checkpoint Inhibitors for the Study of Immune-related Adverse Events","MIRAE","Inclusion Criteria:\n\n* \\>= 18 years of age\n* cancer patients treated with ICI therapy (e.g., anti-CTLA-4, anti-PD-1, anti-PD-L1, and combinations)\n* patients with primary autoimmune or autoinflammatory diseases that resemble immune-related adverse events (irAEs)\n* healthy volunteers with non-inflammatory disorders, and without any history of cancer\n\nExclusion Criteria:\n\n* Participants not able to provide informed consent","18 Years","100 Years",{"count":80,"type":22},1000,"60 Months","Immune checkpoint inhibitors (ICI) are among the most promising approaches to fighting cancer. However, a substantial percentage of patients experience off-target adverse effects in the form of mild to severe inflammation in different organs, commonly called immune-related adverse events (irAEs). irAEs can lead to treatment discontinuation, or can be life-threatening in extreme cases. The causes of irAEs are largely unknown and there are no reliable predictive biomarkers. The Montreal Immune-Related Adverse Events (MIRAE) study collects clinical information and biospecimens (blood, tissue, stool) from cancer patients treated with ICI to facilitate research on the identification of predictive biomarkers of irAEs, their causes, and the design of effective management strategies.",[84,29,85,86],"Cancer","Inflammatory Reaction","Autoimmune Diseases",[88,89,90,91,92,93,94,95,96,97,98,99],"irAEs","ICI (ICB)","CTLA-4","PD-1","PDL-1","Pembrolizumab","Nivolumab","Ipilimumab","Cemiplimab","Atezolizumab","Avelumab","Durvalumab","2026-01-30",{"date":102,"type":34},"2026-02-03",{"date":104,"type":34},"2020-01-21",{"date":106,"type":22},"2030-01",{"name":108,"class":41},"Sir Mortimer B. Davis - Jewish General Hospital",{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":115,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":77,"maxAge":4,"enrollmentInfo":117,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":129,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":42},"100395582","immune-responsiveness-and-outcome-after-aortic-valve-surgery-measure-100395582","NCT04430972","Immune Responsiveness and Outcome After Aortic Valve Surgery (Measure)","Is Pre-operative Impaired imMune rEsponsiveness Associated With Adverse Outcome Following Aortic Valve Replacement SURgEry (MEASURE)","Measure","Inclusion Criteria:\n\n• Patients undergoing first-time open aortic valve replacement surgery\n\nExclusion Criteria:\n\n* Age less than 18y (capacity to consent)\n* Ongoing sepsis (immunomodulatory effects, established influence on outcome from surgery)\n* Immunosuppressive therapy\n* Suffering from known immunosuppressive disease\n* Pregnancy (immunosuppressive aspects to pregnancy)",{"count":118,"type":22},150,"There is considerable morbidity and mortality associated with cardiac surgery. Currently little effort is made to quantify how well the immune system of an individual can cope with inflammation or infection to which they are exposed during surgery.\n\nThe investigators have previously demonstrated that having higher pre-operative antibody levels is associated with a lower risk of infection and a shorter stay in hospital after cardiac surgery.\n\nThe investigators aim to study 150 patients undergoing aortic valve replacement and explore their dynamic immune responsiveness. The investigators will determine if this response is correlated with the post-operative outcome (development of post-operative infection or increased length of hospital stay).\n\nThe investigators will compare this response with the previously measured static markers of immune competence and also with a novel device that may give a more rapid measure of dynamic immunity.\n\nThe investigators will approach patients in the cardiac surgical pre-assessment clinic to see if they are willing to participate in the study.\n\nImmediately once under anaesthetic blood will be taken for testing and then again at the end of surgery, 24h after surgery, at discharge from hospital, and at follow-up clinic approximately 4 weeks later. There will be no additional needle insertions on top of those routinely performed. The investigators will collect data from the routine observations as far as 1 year after surgery.\n\nIf the investigators can show an association between immune function and subsequent post-operative outcome it may be possible to determine ways to improve outcomes for patients undergoing heart surgery.\n\nThis might include better information on risks and benefits of surgery, actively boosting immune function (vaccination, immune-nutrition), passively improving immunity (administering antibodies), or consider current alternatives to open heart surgery where the threat of infection or inflammation may be markedly reduced (eg trans-catheter aortic valve implantation)",[121,122,29],"Aortic Valve Disease","Surgery--Complications",[124,125,126,127,128],"staphylococcus","EndoCAb","Immunity","Cardiac Surgical Procedure","sepsis","NOT_YET_RECRUITING","2024-11-15",{"date":132,"type":34},"2024-11-18",{"date":134,"type":22},"2025-09",{"date":136,"type":22},"2026-09",{"name":138,"class":41},"Barts & The London NHS Trust",{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":145,"eligibilityCriteria":146,"healthyVolunteers":11,"sex":17,"minAge":147,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":23,"phases":150,"briefSummary":151,"conditions":152,"keywords":157,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":167},"100478228","phase-2-effects-of-blocking-tslp-on-airway-inflammation-and-the-epithelial-immune-response-to-exacerbation-triggers-in-patients-with-copd-100478228","NCT05507242","Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD","Effects of Blocking TSLP on Airway Inflammation and the Epithelial Immune-response to Exacerbation Triggers in Patients With COPD A Randomized Double-blind, Placebo-controlled Trial of Tezepelumab UPSTREAM-COPD","UPSTREAM-COPD","Inclusion Criteria:\n\n* Written informed consent\n* A diagnosis of COPD (according to GOLD (GOLD 2021 Report))\n* ≥ 10 packyears smoked (current or ex-smokers)\n* Age 40 years or older\n* Postbronchodilator FEV1 ≥ 30% predicted (and ≥ 1.0L) and \\\u003C 80% predicted\n* Maintenance treatment with LAMA+LABA±ICS (stable dose) for at least 3 months prior to V1\n* ≥1 prednisolon and\u002For antibiotic treated exacerbation in the past 12 months\n* Subjects must demonstrate acceptable inhaler and spirometry techniques during screening (as evaluated and in the opinion of study site staff)\n* Subjects must demonstrate ≥ 70% compliance with daily inhalers during the screening\u002Frun-in\n* Females of childbearing potential who are sexually active with a nonsterilized male partner must use a highly effective method of contraception from the time informed consent is obtained and must agree to continue using such precautions through Week 20 of the study; cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception. Females of childbearing potential are defined as those who are not surgically sterile (ie, bilateral tubal ligation, bilateral oophorectomy, or complete hysterectomy) or postmenopausal (defined as 12 months with no menses without an alternative medical cause).\n\nExclusion Criteria:\n\n* Previous medical history or evidence of an uncontrolled intercurrent illness that in the opinion of the investigator may compromise the safety of the subject in the study or interfere with evaluation of the investigational product or reduce the subject's ability to participate in the study. Subjects with well-controlled comorbid disease (eg, hypertension, hyperlipidemia, gastroesophageal reflux disease) on a stable treatment regimen for 15 days prior to Visit 1 are eligible.\n* Any concomitant respiratory disease that in the opinion of the investigator will interfere with the evaluation of the investigational product or interpretation of subject safety or study results (e.g., cystic fibrosis, pulmonary fibrosis, aspergillosis, active tuberculosis).\n* Current asthma\n* Lung volume reduction surgery for COPD\n* Exacerbation requiring oral corticosteroids or antibiotics (any dose for more than 3 days) 4 weeks prior to Visit 1 or during the run-in period\n* Any use of home oxygen therapy\n* Any clinically relevant abnormal findings in hematology or clinical chemistry (laboratory results from Visit 1), physical examination, vital signs during the screening, which in the opinion of the investigator, may put the subject at risk because of his\u002Fher participation in the study, or may influence the results of the study, or the subject's ability to participate in the study\n* History of cancer: Subjects who have had basal cell carcinoma or in situ carcinoma of the cervix are eligible to participate in the study provided that curative therapy was completed at least 12 months prior to Visit 1. Subjects who have had other malignancies are eligible provided that curative therapy was completed at least 5 years prior to Visit 1.\n* Acute upper or lower respiratory infections requiring antibiotics or antiviral medications within 4 weeks prior to Visit 1 or during the screening period\n* A positive human immunodeficiency virus (HIV) test at screening or subject taking antiretroviral medications, as determined by medical history\n* Positive hepatitis B surface antigen, or hepatitis C virus antibody serology at screening, or a positive medical history for hepatitis B or C. Subjects with a history of hepatitis B vaccination without history of hepatitis B are allowed to enroll.\n* History of sensitivity to any component of the investigational product formulation or a history of drug or other allergy that, in the opinion of the investigator or medical monitor contraindicates their participation.\n* History of any known primary immunodeficiency disorder excluding asymptomatic selective immunoglobulin A or IgG subclass deficiency.\n* Active tuberculosis or history of untreated latent tuberculosis\n* History of anaphylaxis to any biologic therapy.\n* Use of immunosuppressive medication (eg, methotrexate, troleandomycin, oral gold, cyclosporine, azathioprine, intramuscular long-acting depot corticosteroid, or any experimental anti-inflammatory therapy) within 3 months prior to Visit 1.\n* Receipt of any of the following within 30 days prior to Visit 1: immunoglobulin or blood products, or receipt of any investigational nonbiologic agent within 30 days or 5 half-lives prior Visit 1, whichever is longer.\n* Receipt of any marketed or investigational biologic agent within 4 months or 5 half- lives prior to Visit 1, whichever is longer.\n* Pregnant, breastfeeding or lactating females\n* History of chronic alcohol or drug abuse within 12 months prior to Visit 1.\n* Planned surgical procedures requiring general anesthesia or in-patient status for \\> 1 day during the conduct of the study.\n* Unwillingness or inability to follow the procedures outlined in the protocol.\n* Concurrent enrollment in another clinical study involving an investigational treatment.\n* Receipt of any live or attenuated vaccines within 15 days prior to Visit 1.","40 Years",{"count":149,"type":22},80,[25],"A phase 2, multicentre, randomized, double-blind, placebo-controlled, parallel group study to evaluate the effect of tezepelumab on airway inflammation in patients with COPD.",[153,154,155,156,29],"COPD","COPD Exacerbation","COPD Bronchitis","Airway Disease",[153],"2024-08-19",{"date":160,"type":34},"2024-08-21",{"date":162,"type":34},"2022-10-25",{"date":164,"type":22},"2025-12-31",{"name":166,"class":41},"Asger Sverrild",2,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":16,"sex":17,"minAge":175,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":179,"conditions":180,"keywords":183,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":194,"locationsCount":5},"100459749","preterm-immune-system-development-and-response-to-immunization-100459749","NCT05266664","Preterm Immune System Development and Response to Immunization","PRIMI","To be eligible to participate in this study, a preterm infant must meet all following criteria:\n\n* Preterm infant born at gestational age less than 32 weeks (whose mothers did or did not receive a T dap vaccination during pregnancy)\n* Parents\u002F guardians must have sufficient understanding of the Dutch language\n\nTo be eligible to participate in this study, a healthy full-term infant must meet all following criteria:\n\n* healthy full-term infant whose mother received a Tdap vaccination during pregnancy\n* Parents\u002F guardians must have sufficient understanding of the Dutch language\n\nTo be eligible to participate in this study, a mother must meet all following criteria:\n\n\\- Mother of preterm or health full-term infant who are participating in the study\n\nExclusion Criteria:\n\n* Parents\u002Fguardians of the infant are not able or willing to provide informed consent\n* Infant with congenital anomaly which are more likely to cause adverse effects after immunization (for example hemodynamically significant congenital heart defect)\n* Infant with a (possible) HIV infection or immunodeficiency\n* Maternal use of immunosuppressive drugs during pregnancy","1 Day","2 Months",{"count":178,"type":22},145,"In this study the response to vaccination and development of the immune system in very preterm infants upon the current vaccination schedule will be compared to healthy term infants.",[29,181,182],"Preterm","Vaccination Failure",[184,185,186],"immune system development","preterm infant","vaccination","2024-03-19",{"date":189,"type":34},"2024-03-20",{"date":191,"type":34},"2022-12-08",{"date":193,"type":22},"2026-07",{"name":195,"class":41},"Maastricht University Medical Center",{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":202,"eligibilityCriteria":203,"healthyVolunteers":16,"sex":204,"minAge":77,"maxAge":205,"enrollmentInfo":206,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":207,"conditions":208,"keywords":210,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":42},"100439417","prince-study---cohort-study-of-healthy-pregnant-women-followed-by-the-assessment-of-childrens-health-and-immunity-100439417","NCT05002023","PRINCE Study - Cohort Study of Healthy Pregnant Women Followed by the Assessment of Children´s Health and Immunity","PRINCE - PRenatal Identification of Childrens HEalth","PRINCE","Inclusion Criteria:\n\n* Pregnant women\n* \\>18 years of age\n* able to understand and sign the papers of consent\n* singleton pregnancy\n\nExclusion Criteria: :\n\n* \\\u003C18 years of age\n* unable to give consent\n* multiple pregnancy\n* nicotine abuse\n* fetal aberration","FEMALE","50 Years",{"count":80,"type":22},"In the PRINCE study we recruit healthy but also diseased pregnant women into a cohort study, followed by the assessment of children´s health and immunity at birth and during the first 10 years of life. This unique cohort allows for testing the impact of prenatal challenges on children´s health.",[209,29],"Pregnancy",[209,211,212,213],"Immune System","Birth cohort","Fetal Programming","2021-08-20",{"date":216,"type":34},"2021-08-26",{"date":218,"type":34},"2011-02-02",{"date":220,"type":22},"2050-12-31",{"name":222,"class":41},"Universitätsklinikum Hamburg-Eppendorf"]